By MATTHEW HOLT This is the week where the digital health landscape debunks to the HLTH Conference in Vegas to meet, do deals, listen to superannuated rappers and generally have a great time. Speaking as the guy who ran the digital health conference before HLTH emerged, I remain extremely jealous of how Jonathan Weiner, Rich…
In this episode, we’re joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women’s health biotech company. She discusses the funding the company recently received through the Sprint for Women’s Health program. The post MedCity FemFwd: How Celmatix is Using ARPA-H’s Sprint for Women’s Health Funding appeared first on MedCity News.
Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world. The post Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to…
Tariffs on pharmaceuticals. First, President Trump has voiced his goal to impose tariffs on pharmaceutical products made overseas. The New York Times reports: Mr. Trump said in remarks to reporters on Monday that pharmaceutical tariffs would come in the “not too distant future.”“We don’t make our own drugs anymore,” Mr. Trump said. “The drug companies…
Company lands $3 million in seed funding led by Canvas Ventures with participation from CoFound Partners, StoryHouse Ventures and several individual investors
This tracker presents the most recent Medicaid data on renewals and disenrollments available for each state as well as monthly enrollment data during the unwinding period.
Costs are limiting states’ coverage of obesity drugs and could affect other Medicaid priorities States expect national Medicaid enrollment to decline by about 4% and state Medicaid spending to rise by 7% in fiscal year (FY) 2025. These rates follow a larger but anticipated enrollment decline and state spending increase in FY 2024, as pandemic-era…More
HealtheConnections health information exchange is partnering with three social care networks to share data about health-related social needs
Nura Bio aims to treat neurodegeneration with a small molecule designed to block SARM1, a novel target involved in axon degeneration. Following positive Phase 1 results in healthy volunteers, the startup is now preparing for mid-stage clinical testing. The post Neuro Startup Nura Bio Adds $68M to Spare Axons With Its Brain-Penetrating Drug appeared first…
Beleaguered for-profit hospital system will seek to sell off remaining operations outside of California